New combo therapy takes on tough lymphoma
Disease control
Recruiting now
This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC